KR19980701862A - 세포증식 억제처리에 있어서 내성 형성에 대한 5'-치환 뉴클레오시드류의 이용 및 이들 뉴클레오시드류를 함유하는 약제 - Google Patents
세포증식 억제처리에 있어서 내성 형성에 대한 5'-치환 뉴클레오시드류의 이용 및 이들 뉴클레오시드류를 함유하는 약제 Download PDFInfo
- Publication number
- KR19980701862A KR19980701862A KR1019970705259A KR19970705259A KR19980701862A KR 19980701862 A KR19980701862 A KR 19980701862A KR 1019970705259 A KR1019970705259 A KR 1019970705259A KR 19970705259 A KR19970705259 A KR 19970705259A KR 19980701862 A KR19980701862 A KR 19980701862A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- nucleosides
- bvdu
- metabolite
- cell proliferation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
대조군명 | 균주 | 처리 |
pos. | 아드리아마이신-내성F46-WT 세포 | |
neg. | 아드리아마이신-민감성F46-WT 세포 | |
1 | F46-WT 세포 | (E)-5-(2-브로모비닐)-2'-데옥시우리딘 |
2 | F46-WT 세포 | (E)-5-(2-브로모비닐-1-β-D-아라비노푸라노실-우라실 |
3 | F46-WT 세포 | (E)-5-(2-브로모비닐-2'-데옥시-4'-티오우리딘 |
4 | F46-WT 세포 | 5-이오도-2'-데옥시시티딘 |
5 | F46-WT 세포 | 5-이오도-2'-데옥시우리딘 |
6 | F46-WT 세포 | 2'-데옥시-5-트리플루오로메틸우리딘 |
7 | F46-WT 세포 | (E)-5-(2-브로모비닐)-2'-데옥시우리딘(BVDU) |
Claims (11)
- 내성형성을 방해하거나 감소시키는 세포증식 억제처방용 약제의 제조를 위하여 최소한 1종 이상의 세포증식 억제제와 함께 사용되는 5'-치환 뉴클레오시드의 이용.
- 제 1 항에 있어서, 상기 5'-치환 뉴클레오시드는 (E)-5-(2-브로모비닐)-2'-데옥시우리딘(BVDU) 및/또는 그의 대사물질인 것을 특징으로 하는 5'-치환 뉴클레오시드의 이용.
- 제 2 항에 있어서, 상기 대사물질은 (E)-5-(2-브로모비닐)-1-우라실(BVU)인 것을 특징으로 하는 5'-치환 뉴클레오시드의 이용.
- 제 1 항에 있어서, 상기 5'-치환 뉴클레오시드는 (E)-5-(2-브로모비닐)-1-β-d-아라비노푸라노실우라실 및 그의 대사물질인 것을 특징으로 하는 5'-치환 뉴클레오시드의 이용.
- 제 1 항에 있어서, 상기 5'-치환 뉴클레오시드는 (E)-5-(2-브로모비닐)-2'-데옥시-4'-티오우리딘 및/또는 그의 대사물질인 것을 특징으로 하는 5'-치환 뉴클레오시드의 이용.
- 제 1 항에 있어서, 상기 5'-치환 뉴클레오시드는 5-이오도-2'-데옥시시티딘 및/또는 그의 대사물질인 것을 특징으로 하는 5'-치환 뉴클레오시드의 이용.
- 제 1 항에 있어서, 상기 5'-치환 뉴클레오시드는 5-이오도-2'-데옥시우리딘 및/또는 그의 대사물질인 것을 특징으로 하는 5'-치환 뉴클레오시드의 이용.
- 제 1 항에 있어서, 상기 5'-치환 뉴클레오시드는 2'-데옥시-5-트리플루오로메틸우리딘 및/또는 그의 대사물질인 것을 특징으로 하는 5'-치환 뉴클레오시드의 이용.
- 1종 이상의 세포증식 억제제, 전형적인 담체 및 보호물질로 이루어진 약제로서, 제 1 항 또는 제 8 항중 적어도 어느 한항에 의한 5'-치환 뉴클레오시드를 혈액내 최종농도범위가 0.02∼10㎍/㎖되는 분량으로 포함하는 것을 특징으로 하는 약제.
- 제 9 항에 있어서, 상기 5'-치환 뉴클레오시드는 혈액내 최종농도범위가 0.05∼5㎍/㎖되는 분량으로 포함하는 것을 특징으로 하는 약제.
- 제 9 항 또는 제 10 항중 어느 한항에 있어서, 상기 세포증식억제제는 알칼로이드, 알킬화제, 항-대사물질, 항생제 또는 시스플라틴(cisplatin)에서 선택되는 것을 특징으로 하는 약제.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19503152 | 1995-02-01 | ||
DE19503152.0 | 1995-02-01 | ||
DE19545892.3 | 1995-12-08 | ||
DE19545892A DE19545892A1 (de) | 1995-12-08 | 1995-12-08 | Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU |
PCT/DE1996/000169 WO1996023506A1 (de) | 1995-02-01 | 1996-01-31 | Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside |
Publications (2)
Publication Number | Publication Date |
---|---|
KR19980701862A true KR19980701862A (ko) | 1998-06-25 |
KR100330602B1 KR100330602B1 (ko) | 2002-08-22 |
Family
ID=26012025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970705259A KR100330602B1 (ko) | 1995-02-01 | 1996-01-31 | 세포증식억제처치에있어서내성형성에대한5'-치환뉴클레오시드의이용및이들뉴클레오시드류를함유하는약제 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6589941B1 (ko) |
EP (1) | EP0806956B1 (ko) |
JP (1) | JPH11502515A (ko) |
KR (1) | KR100330602B1 (ko) |
AT (1) | ATE222765T1 (ko) |
BR (1) | BR9607109A (ko) |
DE (1) | DE59609590D1 (ko) |
DK (1) | DK0806956T3 (ko) |
ES (1) | ES2180730T3 (ko) |
NO (1) | NO315258B1 (ko) |
PT (1) | PT806956E (ko) |
WO (1) | WO1996023506A1 (ko) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE413881T1 (de) * | 1997-08-08 | 2008-11-15 | Celmed Oncology Usa Inc | Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden |
ATE212661T1 (de) | 1998-01-23 | 2002-02-15 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
DE19842578A1 (de) * | 1998-09-17 | 2000-03-23 | Max Delbrueck Centrum | Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika |
CA2378187C (en) | 1999-07-22 | 2011-09-13 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
US20030212037A1 (en) * | 2000-12-21 | 2003-11-13 | Christopher Boyer | Use of bvdu for inhibiting the growth of hyperproliferative cells |
EP1251836A2 (en) * | 1999-12-23 | 2002-10-30 | NewBiotics, Inc. | Use of bvdu for inhibiting the growth of hyperproliferative cells |
EP1359921A4 (en) | 2001-01-19 | 2006-09-06 | Newbiotics Inc | METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES |
DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
DE10313035A1 (de) * | 2003-03-24 | 2004-10-07 | Resprotect Gmbh | Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen |
US20060269596A1 (en) * | 2005-01-12 | 2006-11-30 | Gary Liversidge | Controlled release compositions comprising an acylanilide |
HUP0600042A3 (en) * | 2006-01-19 | 2012-12-28 | Debreceni Egyetem | New medical use of thiolated pyrimidine-mononucleotides and -nucleosides |
DE102006037786A1 (de) | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20090068286A1 (en) * | 2007-09-11 | 2009-03-12 | Resprotect, Gmbh | Method of treating cancer by administration of 5-substituted nucleosides |
EP2135601A1 (en) * | 2008-06-20 | 2009-12-23 | Capsulution Nanoscience AG | Stabilization of amorphous drugs using sponge-like carrier matrices |
DE102008030091B4 (de) | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
WO2012040127A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1069096A (en) * | 1962-11-23 | 1967-05-17 | Ile De Rech S Scient Et Ind So | New organic derivatives of nucleotides and method for their manufacture |
GB1473148A (ko) * | 1974-09-16 | 1977-05-11 | ||
US4902678A (en) * | 1982-02-12 | 1990-02-20 | Syntex (U.S.A.) Inc. | Anti-viral compositions |
NL8700366A (nl) * | 1987-02-13 | 1988-09-01 | Stichting Rega V Z W | Combinatie van fu met bvdu als middel tegen adenocarcinoom. |
US5250296A (en) * | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
US5831064A (en) | 1996-07-25 | 1998-11-03 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof |
ATE212661T1 (de) | 1998-01-23 | 2002-02-15 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
-
1996
- 1996-01-31 KR KR1019970705259A patent/KR100330602B1/ko active IP Right Grant
- 1996-01-31 EP EP96901696A patent/EP0806956B1/de not_active Expired - Lifetime
- 1996-01-31 WO PCT/DE1996/000169 patent/WO1996023506A1/de active IP Right Grant
- 1996-01-31 PT PT96901696T patent/PT806956E/pt unknown
- 1996-01-31 AT AT96901696T patent/ATE222765T1/de active
- 1996-01-31 DE DE59609590T patent/DE59609590D1/de not_active Expired - Lifetime
- 1996-01-31 JP JP8523173A patent/JPH11502515A/ja active Pending
- 1996-01-31 DK DK96901696T patent/DK0806956T3/da active
- 1996-01-31 BR BR9607109A patent/BR9607109A/pt not_active Application Discontinuation
- 1996-01-31 ES ES96901696T patent/ES2180730T3/es not_active Expired - Lifetime
-
1997
- 1997-07-31 NO NO19973529A patent/NO315258B1/no not_active IP Right Cessation
-
2000
- 2000-03-07 US US09/520,901 patent/US6589941B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0806956A1 (de) | 1997-11-19 |
NO973529D0 (no) | 1997-07-31 |
BR9607109A (pt) | 1997-11-04 |
NO315258B1 (no) | 2003-08-11 |
DE59609590D1 (de) | 2002-10-02 |
ES2180730T3 (es) | 2003-02-16 |
DK0806956T3 (da) | 2003-01-06 |
US6589941B1 (en) | 2003-07-08 |
PT806956E (pt) | 2003-01-31 |
MX9705758A (es) | 1997-10-31 |
WO1996023506A1 (de) | 1996-08-08 |
ATE222765T1 (de) | 2002-09-15 |
EP0806956B1 (de) | 2002-08-28 |
JPH11502515A (ja) | 1999-03-02 |
KR100330602B1 (ko) | 2002-08-22 |
NO973529L (no) | 1997-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR19980701862A (ko) | 세포증식 억제처리에 있어서 내성 형성에 대한 5'-치환 뉴클레오시드류의 이용 및 이들 뉴클레오시드류를 함유하는 약제 | |
US8828451B2 (en) | Akt sensitization of cancer cells | |
Grunwald et al. | Developing inhibitors of the epidermal growth factor receptor for cancer treatment | |
Boss et al. | Clinical evaluation of AZD1152, an iv inhibitor of Aurora B kinase, in patients with solid malignant tumors | |
Emura et al. | A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA | |
ES2535404T5 (es) | Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama | |
HRP20010225A2 (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin | |
EP2435041B1 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
Monnerat et al. | Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer | |
Kaklamani et al. | New targeted therapies in breast cancer | |
Tacconi et al. | Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance | |
CN110573166B (zh) | 用于癌症治疗的吉西他滨衍生物 | |
Grünwald et al. | Development of the epidermal growth factor receptor inhibitor Tarceva™(OSI-774) | |
EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
Gupta et al. | CDK inhibitors as sensitizing agents for cancer chemotherapy | |
Song et al. | A novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells | |
CN112022871A (zh) | 金诺芬在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
Nakata et al. | S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU | |
Juengel et al. | Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells | |
Douglass | Development of ZD1839 in colorectal cancer | |
Sun et al. | Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer | |
US9901594B2 (en) | Pharmaceutical composition and uses thereof | |
Zhang et al. | Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma | |
EP3565547B1 (en) | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof | |
Noujaim et al. | Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
N231 | Notification of change of applicant | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19991228 Effective date: 20011031 Free format text: TRIAL NUMBER: 1999101004766; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19991228 Effective date: 20011031 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130304 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20140305 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20150305 Year of fee payment: 14 |